BT474 and BT474-J4 microarray data

These data provide scientific information to understand the mechanism of action of lapatinib resistance in HER2-positive patients and to test the combination of HER2-targeted agents and GSK1363089 (foretinib) in the clinic by using an acquired lapatinib-resistant cell line. Cell lines (BT474, an HER2-positive and lapatinib-sensitive cell line; BT474-J4, an acquired lapatinib-resistant cell line) were treated with lapatinib alone (1uM), foretinib (GSK1363089) alone (0.1 uM), a combination of lapatinib (1 uM) and foretinib (0.1 uM), or DMSO control for 24 hours. Triplicates were performed.本数据集可为阐明人类表皮生长因子受体2（HER2）阳性患者的拉帕替尼（lapatinib）耐药作用机制提供科学依据，并通过使用获得性拉帕替尼耐药细胞系，在临床场景中评估HER2靶向制剂与GSK1363089（福替尼，foretinib）的联合用药方案。实验采用两类细胞系：BT474（HER2阳性且拉帕替尼敏感的细胞系）与BT474-J4（获得性拉帕替尼耐药细胞系），分别以单一拉帕替尼（1μM）、单一福替尼（GSK1363089，0.1μM）、拉帕替尼（1μM）与福替尼（0.1μM）联合给药，以及二甲基亚砜（Dimethyl Sulfoxide, DMSO）空白对照处理24小时，所有实验均设置三次平行重复。